Other content in this Stream
LMNL Corporate Presentation - January 2020
Liminal BioSciences outlines corporate priorities for 2020
Liminal BioSciences comments on unusual market activity
AMF concludes its review of the refinancing transactions completed by Liminal in April 2019
The AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019.
Quarterly Report Q3 2019
Quarterly Report 2019 Q2
Quarterly Report 2019 Q1
Nasdaq Statement of Corporate Governance Differences
Board of Directors Charter 2019
Code of Ethics and Business Conduct 2019
HR & Corporate Governance Committee Charter 2019
Rare Disease: Alström Syndrome
John and Kay Parkinson are the parents of two children who were diagnosed very late with the ultra-rare disease Alström Syndrome.
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment